Dasicast 60mg Tablet (Daclatasvir)

Dasicast 60mg Tablet is a prescription antiviral medicine containing daclatasvir, a direct-acting antiviral (DAA) that inhibits the hepatitis C virus (HCV) NS5A protein. Daclatasvir 60mg tablet must be used as part of an appropriate combination antiviral regimen; it is not HCV monotherapy. Historically, daclatasvir tablet was authorized in combination with other medicines for chronic HCV infection across selected genotypes and patient populations. The exact partner medicine, treatment duration and role of ribavirin depended on HCV genotype, cirrhosis, prior treatment and other clinical factors.
An important publication point for Madicine: the European marketing authorization for originator Daklinza expired in August 2019 for commercial reasons. Daclatasvir 60mg remains used or available in some jurisdictions, but its place in current therapy varies. The page should therefore avoid presenting an old regimen as universally current first-line treatment.

Dasicast 60mg tablet should be used only for an appropriate specialist-directed indication. The exact treatment setting, combination regimen and duration depend on the diagnosis and current clinical guidance.
Chronic hepatitis C infection: Daclatasvir tablet is an HCV direct-acting antiviral used with other antiviral medicines. The precise regimen must be selected according to the patient's HCV genotype, cirrhosis status, previous treatment, renal/hepatic status and current local guidance.
Combination with sofosbuvir: Daclatasvir 60mg tablet plus sofosbuvir became an important interferon-free regimen in multiple HCV populations. Treatment duration and whether ribavirin was added varied by genotype and disease characteristics.
Special populations: Historically, daclatasvir 60mg-based regimens were studied in patients with advanced liver disease and post-transplant HCV, but current regimen selection should follow contemporary local HCV guidelines.

Daclatasvir tablet acts on the hepatitis C virus NS5A protein. This protein is essential for the multiplication of viral genome and production of new viruses. The medicine inhibits this protein, resulting in rapid reduction in the replication of the virus. In order to prevent resistance, daclatasvir 60mg is recommended only as part of combination therapy.

Clinical evidence for daclatasvir 60mg tablet comes from combination-regimen studies rather than daclatasvir monotherapy. Studies of Dasicast 60mg tablet plus sofosbuvir demonstrated high sustained virologic response rates in several HCV populations, including difficult-to-treat groups.
Historical regulatory product information described genotype- and disease-specific regimens and emphasized use with other antivirals. Modern DAA options have evolved, so treatment selection should be based on current national/international HCV guidance rather than copying an older regimen unchanged.

Common or clinically relevant adverse effects can include:

• Headache
  
• Fatigue
  
• Nausea
• When combined with ribavirin: anemia may occur
• Adverse effects also depend strongly on the partner antiviral regimen

Serious adverse reactions can include:

• Hepatitis B reactivation during or after DAA therapy
  
• Clinically important drug interactions through CYP3A
  
• Serious bradycardia reported with sofosbuvir-containing regimens and amiodarone in relevant DAA labeling/history
  
• Decompensation risk in patients with advanced liver disease depends on regimen and baseline status

Patients should receive medicine-specific instructions about symptoms that require urgent medical attention.

There is no safe basis for choosing a dose simply from the 60mg pack strength. The prescribed regimen depends on the approved indication and patient factors.

These are molecule-level examples/principles from regulatory labeling and are not instructions for self-dosing. The treating specialist determines the actual dose, duration, dose modifications and supportive treatment.

Historical product information advised taking a missed dose as soon as possible if remembered within 20 hours of the scheduled time; if more than 20 hours late, skip it and take the next dose at the usual time. Do not double the dose. The current Dasicast 60mg tablet insert should be checked before publication.

Monitoring is individualized according to the disease, regimen and patient risk factors. It may include:

• ​Baseline HCV RNA and genotype/regimen assessment where relevant
  
• Liver function and cirrhosis status
  
• HBV screening before DAA therapy
  
• Drug-interaction review
  
• HCV RNA response according to current treatment protocol
  
• Adherence and adverse effects
  

1. European Medicines Agency. Daklinza (daclatasvir) EPAR and product information; EU authorization expired August 2019 for commercial reasons. https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza​
2. Historical daclatasvir regulatory product information and HCV combination-regimen clinical evidence https://pmc.ncbi.nlm.nih.gov/articles/PMC5097339/​
3. Current local HCV treatment guidelines and current India-specific Dasicast package insert before publication https://www.ncbi.nlm.nih.gov/books/NBK559965/​
4. Brand-specific Dasicast prescribing information/package insert should remain the primary source for manufacturer, exact presentation, storage, pack configuration and India-specific approved labeling before publication.